A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

16761PEAK-1-NCT07011719OpenA Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaPEAK-1NCT07011719IndustrialAdultTreatmentIIIKidneyAtkins, MichaelGeorgetown University Medical Center : Jamie Manganti; Lombardi Comprehensive Cancer Center : Jamie MangantiGenito-urinaryOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS16801Jamie MangantiJamie Mangantijm3821@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>